$CYDY told investors leronlimab was working for HIV and COVID. The FDA publicly said it wasn't. 25% drop in one day. Settlement submitted to court.

CytoDyn spent 2020 and 2021 promoting leronlimab as a breakthrough therapy for both HIV and COVID-19**,** highlighting positive trial results and ongoing FDA discussions. The investor narrative was confident: meaningful regulatory momentum, strong efficacy data, approval within reach.

**March 30, 2021:** The FDA publicly rebuked the company. The statement was direct, CytoDyn's public claims were misleading, not supported by the data submitted, and the COVID-19 trials showed **no benefit.** The FDA also criticized CytoDyn for promoting an unapproved drug.

**$CYDY dropped over 25% the same day.**

Investors sued alleging CytoDyn's leadership overstated leronlimab's potential, mischaracterized FDA interactions, and withheld critical information about trial results. The $500K settlement has now been submitted to court for approval and we can already [submit claims](http://11th.com/cases/cytodyn-investor-settlement).

Eligible if you held $CYDY between **March 27, 2020 and March 30, 2022.** Payout: \~**$0.04/share.**

*Anyone here follow leronlimab's clinical story closely during the COVID period?*